Results 151 to 160 of about 65,998 (238)

Non‐Metastatic Squamous Cell Carcinoma of the Oropharynx: Primary Surgery or (Chemo)radiotherapy?

Head &Neck, Volume 48, Issue 9, Page 2541-2556, September 2026.
ABSTRACT Background In patients with locally advanced, non‐metastatic oropharyngeal squamous cell carcinoma (OPSCC), surgery‐based and nonsurgical treatment approaches have not been adequately compared in randomized Phase III clinical trials. Current clinical guidelines recommend various surgical and nonsurgical strategies across disease stages for ...
Primož Strojan, Avraham Eisbruch, June Corry, Sandra Nuyts, Pim de Graaf, Luiz P. Kowalski, Jonathan J. Beitler, Sweet Ping Ng, William M. Mendenhall, M. P. Sreeram, Karthik N. Rao, Anna Luíza Damaceno Araújo, Alfio Ferlito   +12 more
wiley   +1 more source

Incidence and impact of pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab: a retrospective analysis. [PDF]

Acta Oncol
Caeyman A, Mammone G, Kinget L, Baldewijns M, De Wever L, Albersen M, Debruyne PR, Demeulenaere O, McTaggart ES, Saraswat S, Berghen C, De Meerleer G, Naulaerts S, Garg AD, Beuselinck B.   +14 more
europepmc   +1 more source

Exceptional therapeutic benefit of imatinib in cKIT‐mutated mucosal melanoma followed by a KIT mutation loss

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Hannah Zillikens, Corinna Scheib, Vicky Peller, Christina Müller, Sebastian Bauer, Ina Pretzell, Klaus Griewank, Antje Sucker, Eva Hadaschik, Felicitas Guntrum, Sven Holger Baum, Alexander Roesch, Selma Ugurel, Dirk Schadendorf, Lisa Zimmer, Elisabeth Livingstone   +15 more
wiley   +1 more source

Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review

Head &Neck, Volume 48, Issue 9, Page 2570-2583, September 2026.
ABSTRACT Objective To provide a comprehensive review of the biological rationale, clinical evidence, and practical perioperative management of immunotherapy for the head and neck surgeon. Summary Background Data Standard treatment for resectable head and neck squamous cell carcinoma (HNSCC) has reached a survival plateau, with over 50% of patients ...
Nicholas Brian Shannon, Bruce Ashford
wiley   +1 more source

Past, present and future of nivolumab: new horizons in immuno-oncology. [PDF]

Front Oncol
Madar IH, Kammarambath SR.
europepmc   +1 more source

Immunotherapeutic Approaches to Head and Neck Squamous Cell Carcinoma: Current Clinical Practice and Future Directions

Head &Neck, Volume 48, Issue 9, Page 2584-2592, September 2026.
ABSTRACT Background Head and neck squamous cell carcinoma (HNSCC) is frequently diagnosed at advanced stages and has historically been associated with poor outcomes. Immune checkpoint inhibition has transformed the therapeutic landscape, offering durable responses in recurrent, metastatic, and locally advanced disease.
Carol R. Bradford, Sreeram M. P., Karthik N. Rao, Orlando Guntinas‐Lichius, Nabil Saba, Alfio Ferlito   +5 more
wiley   +1 more source

Perioperative immune-checkpoint inhibitors for muscle-invasive bladder cancer. [PDF]

Drugs Context
Jang A, Grier AL, Sheng IY, Bari S, Barata PC, Garcia JA, Brown JR.   +6 more
europepmc   +1 more source

Encorafenib‐associated acantholytic dermatosis in collision with eccrine squamous syringometaplasia

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Francisco Meraz‐Torres, Gabi Handgretinger, Andreas Meiwes, Derya Durak, Joana Schroth, Stephan Forchhammer   +5 more
wiley   +1 more source

The Cancer Immunotherapy Thromboembolism Assessment: A Novel Score for Predicting Thromboembolic Events in Melanoma Patients Treated With Immune Checkpoint Inhibition

International Journal of Cancer, Volume 159, Issue 5, Page 1337-1344, 1 September 2026.
Although immune checkpoint inhibitors (ICI) have transformed metastatic melanoma treatment, thromboembolic events (TEEs) remain a serious complication. Moreover, existing risk assessment models were developed prior to ICI use and lack clinical validation.
Tim Zell, Julian Kött, Noah Zimmermann, Greta Ancker, Alexander T. Bauer, Daniel J. Smit, Glenn Geidel, Julian C. Gerwers, Thomas Renné, Sebastian A. Wohlfeil, Jochen Utikal, Stefan W. Schneider, Christoffer Gebhardt   +12 more
wiley   +1 more source

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study. [PDF]

Oncol Ther
Godbert B, Gobbini E, Khalife Y, Decroisette C, Brellier F, Lena H, Fleuriet A, Zysman M, Egenod T, Girard N.   +9 more
europepmc   +1 more source